Research Paper Volume 12, Issue 18 pp 18676—18692

Identification of genomic alterations and associated transcriptomic profiling reveal the prognostic significance of MMP14 and PKM2 in patients with pancreatic cancer

Figure 4. MMP14 and PKM2 are regulated by KRAS mutation, TP53 mutation and CDKN2A deletion and associated with the prognosis of patients with pancreatic cancer. (A) Venn diagram depicted that six genes E2F7, CDC6, MMP14, PLK1, VASP and PKM2 were associated with the prognosis of patients with pancreatic cancer in TCGA, GSE71729, GSE78229 and GSE79668 datasets. (B) Unsupervised clustering heatmap demonstrated the expression levels of E2F7, CDC6, MMP14, PLK1, VASP and PKM2 in TCGA PAAD datasets. (C) Box plots showed the MMP14 and PKM2 expression levels (log2 normalization count) in TCGA pancreatic cancer patients with or without genomic alterations. P values were performed using Student’s t test. (D) Kaplan-Meier survival analysis was used to compare the overall survival of MMP14 or PKM2 highly expressed patients (red) with MMP14 or PKM2 lowly expressed patients (black) in TCGA, GSE71729, GSE78229 and GSE79668 datasets. P values were generated from Log-rank test.